comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 17:02:44 - browse：63842

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

hotspot

WSS

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Surprise medical billing ban raises prices elsewhere

MD Anderson's Padmanee Sharma responds to research credit suit

Medicare Advantage enrollment hits roughly 33.4 million

Opioid cravings were reduced by anti

Ukraine seeks to reclaim its role as a hub for clinical trials

entertainment

comprehensive

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Novavax promises a turnaround & Lilly roils the obesity market

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Medical records are filled with copy

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Activists slam private health insurers over coverage restrictions

WATCH: Why do our ears pop?

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

focus

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Secretariat’s lessons for human medicine

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Surprise medical billing ban raises prices elsewhere

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

hotspot

leisure time

leisure time

hotspot